liquids and its inherent therapeutic potential, PS has been proposed to be used as a carrier for antibiotics [4] , corticosteroids, and recombinant adenoviral vectors [5] . From a formulation standpoint, the lipid-based drug delivery system should be compatible with lung tissue, and not readily elicit immunogenic reactions, since they resemble physiological PS in components. It is expected that PS could also be employed as a protein and peptide carrier in pulmonary delivery.
Based on previous studies [6, 7] , we prepared 4 formulations of artificial pulmonary surfactants (APS) as carriers of insulin (INS) as a model drug. The in vivo bioavailability of INS-APS and the correlation between minimal surface tension and the bioavailability of INS-APS were investigated after intratracheal instillation (IT) in normal rats. Injury to the lungs of normal rats after 7 d of consecutive administration was primarily investigated.
Materials and methods
Materials 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, Sigma, St Louis, MO, USA); L-α-phosphatidyl-DLglycerol sodium salt (PG, Sigma, USA); tyloxapol (Tyl, Sigma, USA); 1-hexadecanol (Hex, Acros Organics, Pittsburgh, PA, USA); lecithin (Shanghai Boao Bioscience Co, Shanghai, China); palmitic acid (PA, Sinopharm Group Chemical Reagent Co, Shanghai, China); INS powder (Jiangsu Wanbang Biochemical & Pharmaceutical Co, Xuzhou, China); enzymatic glucose reagent kit (Shanghai Shenfeng Biochemistry Reagent Factory, Shanghai, China); Radioimmunoassays (RIA) kit (Beijing Furui Bioengineering Co, Beijing, China). Other chemicals were of Analytical reagents (AR). ZX-98 rotavapor (Shanghai Organic Chemical Institute, Shanghai, China); KPS-2 supersonic microniser (Shanghai Kaibo Supersonic Apparatus Factory, Shanghai, China); particle size system (Nicomp 380/ZLS, Santa Barbara, CA, USA); pulsating bubble surface tensiometer (modified based on Enhorning's method [6, 8] ); UV-754 ultraviolet spectrophotometer (Shanghai Analytical Instrument General Factory, Shanghai, China); photomicroscope (Olympus BX-50, Tokyo, Japan); and Wistar rats (bred by the laboratory animal department of Fudan University, Shanghai, China). INS-APS and blank DPPC dispersions employed in this experiment were produced within our laboratory.
Preparation of INS-APS The composition of 4 APS dispersions were as follows: DPPC/lecithin/PA (6:3:1, w/w/w), DPPC/Hex/Tyl (13.5:1.5:1, w/w/w), DPPC/PG (3:1, w/w), DPPC/ Tyl (13.5:1, w/w). DPPC/lecithin/PA, DPPC/Hex/Tyl and DPPC/PG were prepared by a thin-film sonication method.
Various lipids and additives dissolved in ethanol/chloroform were mixed; the organic phase was evaporated by rotavapor and the residual solvent was removed in a vacuum overnight. Lipids and additives formed a thin film on the flask wall and were hydrated in sterile saline at 50 °C for 2 h, then sonicated for 5 min for further dispersing. DPPC/Tyl was prepared by a direct sonication method. DPPC and Tyl were mixed in sterile saline and sonicated for 5 min [9] . The resulting APS dispersions were filtrated through a 0.45 µm filter. INS powder (28 IU/mg) was solubilized with 1 mL of 0.1 mol/L HCl; a sterile saline solution was added to make the final INS concentration of 4 IU/mL.
An aliquot of the INS solution was added to each of the APS dispersions and sonicated for 2 min. Final preparations of INS-APS (INS/DPPC/lecithin/PA, INS/DPPC/Hex/Tyl, INS/DPPC/PG, INS/DPPC/Tyl) dispersed in saline contained 13.5 mg/mL DPPC and 4 IU/mL INS.
Measurement of particle size The particle sizes of all INS-APS were determined with a laser diffraction particle size analysis system.
Measurement of minimal surface tension (γ min ) The minimal surface tension of APS and INS-APS was determined by a pulsating bubble surface tensiometer (modified based on Enhorning's method [6, 8] ). Each dispersion (5 µL) was added to the gas-liquid interface of the air bubble. According to the shape of the bubble during pulsating cycles at the temperature of 37 °C, the γ min was calculated according to the Bashforth-Adams formulation [10] .
Pharmacodynamic and pharmacokinetic experiments INS preparations administration In all of the in vivo
experiments, healthy Wistar rats [body weight (BW) 200±30 g] had free access to food and water. Before the experiment, the animals fasted overnight (14 h). Forty-two male rats were divided into 7 groups randomly as follows: (1) All of the rats were anaesthetized with aether and attached to a board with an elevation of 80° to the horizontal plane. Rat tongues were drawn out and each INS formulation was instilled intratracheally into the lungs through a syringe while the rats were inspiring. The rats were maintained for 30 s on the board after drug delivery and then the board was rotated to a 30° horizontal elevation for 1 min. 0.4 mL of blood was taken from the tail vein shortly before drug administration for a baseline sample and subsequently 15, 30, 60, 90, 120, 180, 240, 300, and 360 min after dosing to determine respective serum glucose and INS levels. The experimental design of the animal study in this paper was approved by the appropriate ethical committee on animal studies at Fudan University (China).
Calculation of the area above the curve (AAC) and the area under the curve (AUC) of INS formulations Blood samples were centrifuged at 3000 r/min for 10 min at 4 °C, and the serum glucose level was determined immediately according to the glucose oxidase method. The serum INS level was quantitated by a double-antibody radioimmunoassay using a commercial RIA kit. The percentage of serum glucose change and the serum INS level were plotted as a function of time. The area above the percentage serum glucose change versus time curve (AAC) and the area under the serum INS level versus time curve (AUC) were calculated by the linear trapezoidal method. The relative pharmacological bioavailability (f) [11] and relative bioavailability (F) [12] were calculated by the following formulations:
Pilot study on lung injury in rats In lung injury experiments, healthy Wistar rats (BW 200±30 g) had free access to food and water. Thirty-six male rats were divided into 6 groups randomly as follows: (1 Groups 1, 2, 3, 4, and 5 were consecutively administered INS preparations for 7 d (about 0.2 mL INS-APS per rat) and once a day as per the above mentioned method. The control group (normal rats) was fed with lab chow and water without any administration for 7 d. All of the rats were sacrificed on d 7. The changes of the pulmonary edema index and histopathology of lungs were investigated to evaluate the severity of injury to the lungs.
Pulmonary edema index All of the rats were sacrificed on d 7. The whole lungs were removed and dissected. The right-sided lungs were weighed both before drying (W W ) and after drying (W D ) at 60 °C. The pulmonary edema index was calculated by the following equation: Index=W W /W D [12] . Histopathology observation The left-sided lungs were fixed in 10% formalin, dehydrated, embedded in paraffin, sectioned using a microtome, and stained using hematoxylineosin. The lung slices were observed under a photomicroscope and photographic records were taken.
Statistical analysis Data were expressed as mean±SD. Statistical significant differences were evaluated with an analysis of ANOVA in the groups and Bonferroni (Dunnett) t-test between 2 groups.
Results
Appearance and particle size of INS-APS All APS dispersions and INS-APS were dispersed in sterile saline homogeneously and had emulsive lights. The appearance of APS and INS-APS particles were circular and smooth. F INS/DPPC/lecithin/PA . DPPC dispersion alone seemed to have no effect on the serum INS level. The duration of glucose levels maintained at a level below 80% after pulmonary delivery of INS were summarized. This was provided as a means of evaluating the prolonged hypoglycemic effects of the INS preparations [13] . As displayed in Figure 1 , the duration of IT of INS-APS were all above 6 h, which was longer than the hypoglycemic effect of an INS solution sc injection (4 h) and IT (5 h Histopathological examination of lungs As shown in Figure 3 , following IT for 7 consecutive days, thickened alveolar septa were clearly observed in the lung slices in rats administrated with INS solution (Figure 4B) , as compared to the control group ( Figure 4A ). Diffused disruption of alveolar capillaries with leakage of red blood cells into the alveolar lumina and lung interstitium was generally noted in the INS solution group. Prominent inflammatory cell infiltration and lung vascular epithelial degeneration were also observed in this group. The pathological changes became less severe in the slices after INS-APS administration ( Figure 4C-4F ). The width of alveolar septa was slighter broader than the control group. Disruption of the alveolar wall and leakage of red blood cells were not evident. There was only very slight visible epithelial degeneration and no other alveolar structural changes observed in the INS-APS groups, as compared with the control groups. Inflammatory cell infiltration was still found in some samples although this was only negligible.
Discussion
The natural PS is a complex mixture produced by alveolar type II cells in lung. It can stabilize lungs for efficient respiration and prevent or treat RDS by reducing alveolar surface tension and increasing lung compliance. Due to the small diameter of peripheral airways, fluid with a high surface tension requires high pressure delivery for distribution. Studies have shown that PS is superior to saline in distributing a radioactive colloid within healthy lungs, and is more homogenous and peripheral in lungs than saline [14] . PS carry out this function by forming a film at the air-liquid interface. This film mainly consists of lipids and surfactant proteins. The hydrophilic polar heads of amphiphilic phospholipid molecules remain in water while the fatty acids turn towards air. The phospholipids molecules interluding in water affect the affinity in molecules. Due to this film, surface tension is lowered and undergoes considerable changes during the respiratory cycle [15] .
Of the many components of natural PS, DPPC appears to have the necessary thermodynamic properties to reduce surface tension effectively. However the high cohesive energy of compressed monolayers of disaturated long-chain fatty acids, combined with significant hydration of the headgroups, inhibits the rapid spreading of DPPC molecules in an air/liquid interface. Therefore, the synergistic effect of other lipids are required to reduce the cohesion of DPPC in lipid mixture, such as PG, cholesterol and free PA, and of several lung specific proteins [16] . Most research on APS have documented a potential for antigenicity due to the presence of a foreign protein [17, 18] . In this paper, DPPC was used as the key ingredient and other components were employed to prepare APS dispersions. It was shown that APS could decrease the surface tension at the air/liquid interface significantly and also enhance INS absorption with resulting alleviation of lung injury.
This experiment showed that the γ min value of the 4 INS-APS were all lower than DPPC dispersion alone. DPPC and PG are generally considered as components of PS; in this study they were employed as 1 formulation of APS. Lecithin contains unsaturated fatty acid residues which probably enhance the fluidity of the DPPC films [16] ; furthermore, the addition of PA often makes the dispersion more homogeneous [19] . DPPC/lecithin/PA was designed and added to INS. In the DPPC/Hex/Tyl dispersion, Hex acts as a spreading agent and Tyl as a dispersion agent [20] . were higher than INS/DPPC/lecithin/PA, and similar trends were noted for the relative bioavailability of INS-APS. The correlation between γ min and f, and F suggested that the decrease of the γ min values of APS and INS-APS directly affected f and F. It was also revealed that the in vivo hypoglycemic effect could be predicted with the γ min values of INS-APS. The mechanism whereby INS absorption was enhanced is believed to be via an APS-mediated decrease in the γ min of the gas-liquid interface in alveolar tissue. This property appears to increase the facility and affect spreading, which in return increases the absorption area and produces greater INS absorption with APS.
In comparison to the pulmonary edema index, it was concluded that INS-APS could decrease lung injury compared with the INS solution following 7 d of consecutive IT. The lower index was obtained by INS/DPPC/PG and INS/DPPC/ Tyl, which might contribute to the lower γ min value of the 2 INS-APS. Combining the results of the pulmonary edema index and histopathology examination, it was suggested that the pulmonary delivery of INS-APS might reduce the severity of any lung injury during administration and would thus be more appropriate for pulmonary delivery than the INS solution.
In summary, DPPC/Hex/Tyl, DPPC/PG, and DPPC/Tyl, with their low γ min , appeared to be effective absorption enhancers and significantly decreased lung injury. INS/DPPC/ Tyl and INS/DPPC/PG in this study were shown to be efficient INS pulmonary delivery carriers with several advantages over drug preparations current utilized clinically.
